

**BSRBR-RA Event of Special Interest (ESI) Report
LYMPHOPROLIFERATIVE MALIGNANCY**

Study ID: HRN: Patient Initials:	Gender: Date of Birth: NHS Number:
Event Date:	Biologic/biosimilar at time of event: Product Batch Number:

Event Details

What was the diagnosis? (Please include site)

Histopathological classification & Staging/ Radiology: (If known, please enclose a copy of the results)

Treatment Regime:

Withdrawal of MTX, no other treatment given

Withdrawal of biologic/biosimilar, no other treatment given

Surgery Chemo regime Rituximab Radiotherapy

Tissue EBV Status: Positive Negative Unknown

Past history of Sjögren's disease? YES NO DON'T KNOW

Please provide name & hospital of doctor treating the malignancy if available:

Positive family history of cancer? YES NO DON'T KNOW

Do you believe there is a possibility that this adverse event was related to the biologic/biosimilar drug used to treat RA? Yes No Unknown

If **Yes** please confirm which drug: _____

What was the outcome of the event?

Resolved Not Resolved Resolved with sequelae Fatal

Form completed
By: _____
On: ____/____/____

Return ESI/s to: BSRBR-RA. The University of Manchester,
Unit 4 Rutherford House, 40 Pencroft Way, Manchester Science Park
Manchester, M15 6SZ. You can also fax these to: 0161 2751640